You are here

Lonza maintains 2019 outlook after 'solid start' in Q1


SWISS drug ingredients maker Lonza Group is maintaining its full-year outlook amid positive momentum in its core healthcare businesses and headwinds in its speciality ingredients segment, the company said in a business update provided on Thursday.

The company described...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to